Share an update on the Phase 3 P303 immunogenicity trial of enhanced mRNA-1010
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 30 Sep 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to share an update on P303 in the third quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company's 10-Q filed November 2023 states that it announced P303 interim results for mRNA-1010 in September 2023, before the September 30, 2023 deadline.
-
A Moderna 10-Q filed 2023-11-03
“In September 2023, we announced that our updated vaccine candidate against seasonal influenza, mRNA-1010, met all co-primary endpoints in an interim analysis of the P303 study” ✓ confirmed on the page
-
A Moderna 10-K filed 2024-02-23
“In September 2023, we announced the P303 immunogenicity and safety study of mRNA-1010 met all 8 co-primary endpoints” ✓ confirmed on the page
Market reaction: the shares moved +2.0% against the S&P 500 over the three sessions around the disclosure (2 Nov 2023 to 7 Nov 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Share
- Deliverable
- Update on Phase 3 P303 enhanced mRNA-1010 immunogenicity trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MRNA-006204 · Corrections policy